PCRX News and Press, Pacira BioSciences Inc. From 02/28/23

Pacira BioSciences press release ( NASDAQ: PCRX ): Q4 Non-GAAP EPS of $0.80 misses by $0.03 . Revenue of $172M (+8.0% Y/Y) misses by $1.32M . Pacira ended the fourth quarter of 2022 with cash, cash equivalents and available-for-sale investments (“cash”) o...

— Record revenues of $667 million in 2022 — — Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million — — EXPAREL surpasses the 12 million patient mark — — Conference call today at 8:30 a.m. ET — ...

Pacira BioSciences ( NASDAQ: PCRX ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open. The consensus EPS Estimate is $0.83 (-14.4% Y/Y) and the consensus Revenue Estimate is $173.32M (+8.9% Y/Y). Over the last 2 years, PCRX has beaten...

DAYTONA BEACH, Fla. and TAMPA, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), a company committed to non-opioid pain management and regenerative health solutions, and the Ladies Professional Golf Association (LPGA) announced today a multi-year sponsorship that m...

TAMPA, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2022 financial results before the open of the U.S. markets on Tuesday, February 28, 2023. Following the release, the company wil...

The shares of pain therapy developer Pacira BioSciences ( NASDAQ: PCRX ) gained in the morning hours Tuesday after Wedbush Securities started its coverage with an Outperform recommendation citing a compelling buying opportunity. Pacira ( PCRX ) has lost more than 37% over the past...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Higher interest rates created a difficult year for ...

The following slide deck was published by Pacira BioSciences, Inc. in conjunction with this event. For further details see: Pacira BioSciences (PCRX) Presents At 41st Annual Healthcare Conference - Slideshow

Summary Reluctancy of management to provide forward estimates points to challenges in end-markets, and a key risk by estimation. Sequential sales growth looks to have stalled based on the monthly earnings releases, but we'll have to wait and see. Investor reaction to commentary on p...